AxoGen price target raised to $42 from $34 at Citizens

Citizens raised the firm’s price target on AxoGen (AXGN) to $42 from $34 and keeps an Outperform rating on the shares. In December, AxoGen’s Avance Nerve Graft received FDA BLA approval, a major 2025 catalyst expected to improve commercial coverage for the “AxoGen Algorithm” as the company expands into Extremities, Breast, OMF/H&N, and Prostate markets, the analyst tells investors in a research note.